T22319 |
DTP3
|
1809784-29-9
|
99.57%
|
|
DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
|
T6933 |
Peficitinib
|
944118-01-8
|
98.67%
|
|
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
|
T2460 |
JAK 3 inhibitor IV
|
58753-54-1
|
98%
|
|
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be...
|
T2653 |
SB1317
|
1204918-72-8
|
100%
|
|
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
|
T11710L |
JAK-IN-5 hydrochloride
|
2751323-21-2
|
|
|
JAK-IN-5 hydrochloride is a JAK inhibitor [1].
|
T11709 |
JAK3 covalent inhibitor-1
|
2300106-50-5
|
98%
|
|
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs.
|
T11713 |
JBJ-02-112-05
|
2748162-29-8
|
98%
|
|
JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].
|
T16995 |
TAS05567
|
1429038-15-2
|
98%
|
|
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
|
T77943 |
SJ1008030 TFA
|
|
98%
|
|
SJ1008030 (compound 8) TFA is a selective JAK2-degrading PROTAC that inhibits the growth of MHH-CALL-4 leukemia cells with an IC50 of 5.4 nM, indicating its pote...
|
T78175 |
JAK-IN-25
|
2127110-22-7
|
98%
|
|
JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3. It also demonstrates...
|
T78189 |
JAK-IN-26
|
2417134-93-9
|
98%
|
|
JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in suppressin...
|
T78207 |
Lepzacitinib
|
2321488-47-3
|
98%
|
|
Lepzacitinib, a Janus kinase inhibitor, specifically targets JAK 1/3. It demonstrates an anti-inflammatory effect and efficacy in inhibiting atopic dermatitis as...
|
T78708 |
JAK/HDAC-IN-2
|
|
98%
|
|
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations. This compou...
|
T79078 |
JAK1-IN-10
|
2416858-88-1
|
98%
|
|
JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
|
T79079 |
JAK1-IN-11
|
2427608-43-1
|
98%
|
|
JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.4...
|
T79110 |
JAK-IN-27
|
2673176-36-6
|
98%
|
|
JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM for...
|
T79116 |
JAK-IN-28
|
2445500-22-9
|
98%
|
|
JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].
|
T79222 |
JAK-IN-29
|
|
98%
|
|
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].
|
T79235 |
JAK-IN-30
|
2891469-99-9
|
98%
|
|
JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) ...
|
T79581 |
JAK2-IN-9
|
2568842-26-0
|
98%
|
|
Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM. It effectively inhibits the phosphorylation of JAK2, STAT3, and STAT5, posse...
|